Bacterial antitumor therapy has great application potential given its unique characteristics,including genetic manipulation, tumor targeting specificity and immune system modulation. However,the nonnegligible side eff...Bacterial antitumor therapy has great application potential given its unique characteristics,including genetic manipulation, tumor targeting specificity and immune system modulation. However,the nonnegligible side effects and limited efficacy of clinical treatment limit their biomedical applications. Engineered bacteria for therapeutic applications ideally need to avoid their accumulation in normal organs and possess potent antitumor activity. Here, we show that macrophage-mediated tumor-targeted delivery of Salmonella typhimurium VNP20009 can effectively reduce the toxicity caused by administrating VNP20009 alone in a melanoma mouse model. This benefits from tumor-induced chemotaxis for macrophages combined with their slow release of loaded strains. Inspired by changes in the tumor microenvironment, including a decrease in intratumoral dysfunctional CD8+T cells and an increase in PDL1 on the tumor cell surface, macrophages were loaded with the engineered strain VNP-PD1nb, which can express and secrete anti-PD1 nanoantibodies after they are released from macrophages. This novel triple-combined immunotherapy significantly inhibited melanoma tumors by reactivating the tumor microenvironment by increasing immune cell infiltration, inhibiting tumor cell proliferation, remodeling TAMs to an M1-like phenotype and prominently activating CD8+T cells. These data suggest that novel combination immunotherapy is expected to be a breakthrough relative to single immunotherapy.展开更多
Tumor growth is an angiogenesis-dependent process and accompanied by the formation of hypoxic areas.Tumstatin is a tumor-specific angiogenesis inhibitor that suppresses the proliferation and induces the apoptosis of t...Tumor growth is an angiogenesis-dependent process and accompanied by the formation of hypoxic areas.Tumstatin is a tumor-specific angiogenesis inhibitor that suppresses the proliferation and induces the apoptosis of tumorous vascular endothelial cells.VNP20009,an attenuated Salmonella typhimurium strain,preferentially accumulates in the hypoxic areas of solid tumors.In this study,a novel Salmonella-mediated targeted expression system of tumstatin(VNP-Tum5)was developed under the control of the hypoxia-induced J23100 promoter to obtain anti-tumor efficacy in mice.Treatment with VNP-Tum5 effectively suppressed tumor growth and prolonged survival in the mouse model of B16F10 melanoma.VNP-Tum5 exhibited a higher efficacy in inhibiting the proliferation and inducing the necrosis and apoptosis of B16F10 cells in vitro and in vivo compared with VNP(control).VNP-Tum5 significantly inhibited the proliferation and migration of mouse umbilical vascular endothelial cells to impede angiogenesis.VNP-Tum5 downregulated the expression of anti-vascular endothelial growth factor A,platelet endothelial cell adhesion molecule-1,phosphorylated phosphoinositide 3 kinase,and phosphorylated protein kinase B and upregulated the expression of cleaved-caspase 3 in tumor tissues.This study is the first to use tumstatin-transformed VNP20009 as a tumor-targeted system for treatment of melanoma by combining anti-tumor and anti-angiogenic effects.展开更多
基金supported in part by grants from the National Natural Sciences Foundation of China (82130106)Jiangsu Provincial Department of Science and Technology (BK20192005, China)+1 种基金Changzhou Bureau of Science and Technology (CJ20210024, CZ20210010, China)Jiangsu TargetPharma Laboratories Inc., China
文摘Bacterial antitumor therapy has great application potential given its unique characteristics,including genetic manipulation, tumor targeting specificity and immune system modulation. However,the nonnegligible side effects and limited efficacy of clinical treatment limit their biomedical applications. Engineered bacteria for therapeutic applications ideally need to avoid their accumulation in normal organs and possess potent antitumor activity. Here, we show that macrophage-mediated tumor-targeted delivery of Salmonella typhimurium VNP20009 can effectively reduce the toxicity caused by administrating VNP20009 alone in a melanoma mouse model. This benefits from tumor-induced chemotaxis for macrophages combined with their slow release of loaded strains. Inspired by changes in the tumor microenvironment, including a decrease in intratumoral dysfunctional CD8+T cells and an increase in PDL1 on the tumor cell surface, macrophages were loaded with the engineered strain VNP-PD1nb, which can express and secrete anti-PD1 nanoantibodies after they are released from macrophages. This novel triple-combined immunotherapy significantly inhibited melanoma tumors by reactivating the tumor microenvironment by increasing immune cell infiltration, inhibiting tumor cell proliferation, remodeling TAMs to an M1-like phenotype and prominently activating CD8+T cells. These data suggest that novel combination immunotherapy is expected to be a breakthrough relative to single immunotherapy.
基金supported in part by grants from the National Natural Sciences Foundation of China(No.82130106)the Jiangsu Provincial Department of Science and Technology(No.BK20192005).
文摘Tumor growth is an angiogenesis-dependent process and accompanied by the formation of hypoxic areas.Tumstatin is a tumor-specific angiogenesis inhibitor that suppresses the proliferation and induces the apoptosis of tumorous vascular endothelial cells.VNP20009,an attenuated Salmonella typhimurium strain,preferentially accumulates in the hypoxic areas of solid tumors.In this study,a novel Salmonella-mediated targeted expression system of tumstatin(VNP-Tum5)was developed under the control of the hypoxia-induced J23100 promoter to obtain anti-tumor efficacy in mice.Treatment with VNP-Tum5 effectively suppressed tumor growth and prolonged survival in the mouse model of B16F10 melanoma.VNP-Tum5 exhibited a higher efficacy in inhibiting the proliferation and inducing the necrosis and apoptosis of B16F10 cells in vitro and in vivo compared with VNP(control).VNP-Tum5 significantly inhibited the proliferation and migration of mouse umbilical vascular endothelial cells to impede angiogenesis.VNP-Tum5 downregulated the expression of anti-vascular endothelial growth factor A,platelet endothelial cell adhesion molecule-1,phosphorylated phosphoinositide 3 kinase,and phosphorylated protein kinase B and upregulated the expression of cleaved-caspase 3 in tumor tissues.This study is the first to use tumstatin-transformed VNP20009 as a tumor-targeted system for treatment of melanoma by combining anti-tumor and anti-angiogenic effects.
